Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Meso crawled time : 01:00 save search
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Published: 2024-02-15 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 1.04%
H: 5.13%
C: 4.87%
revascor drug disease children food designation heart grants
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
Published: 2023-07-31 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 5.0%
H: 2.38%
C: -4.76%
report
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
Published: 2023-06-05 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 0.28%
H: 2.47%
C: 0.55%
Mesoblast Completes Private Placement
Published: 2023-04-26 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
| Email alert
Add to watchlist
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
Published: 2023-03-08 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 10.89%
H: 18.45%
C: 11.61%
fda disease children application resubmission license response
Mesoblast Financial Results and Corporate Update Webcast
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.31%
financial update results
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
Published: 2022-12-23 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: -1.97%
Mesoblast Corporate Update and Financial Results Webcast
Published: 2022-08-30 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -0.36%
H: 1.43%
C: -2.15%
update results
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
Published: 2022-07-12 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -2.52%
H: 3.8%
C: 1.48%
management heart therapeutics
Operational Highlights and Financial Results for the Period Ended March 31, 2022
Published: 2022-06-01 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -4.99%
H: 3.79%
C: 0.87%
Appendix 4C Quarterly Activity Report
Published: 2022-04-29 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 4.7%
H: 2.06%
C: -3.17%
report
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
Published: 2022-03-24 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 2.4%
H: 4.45%
C: 3.98%
fda vaccine
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
Published: 2022-02-01 (Crawled : 01:00) - biospace.com/
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 4.33%
H: 0.0%
C: 0.0%
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
Published: 2022-02-02 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -3.44%
H: 0.0%
C: 0.0%
Mesoblast to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
Published: 2022-01-24 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -2.89%
H: 3.23%
C: 2.23%
health thc conference group
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
Published: 2021-12-30 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 0.0%
H: 2.3%
C: -0.21%
fda disease cel children
FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
Published: 2021-12-16 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 17.51%
H: 2.6%
C: -0.8%
fda
Update on Novartis Agreement
Published: 2021-12-14 (Crawled : 01:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: 0.17%
H: 0.5%
C: -0.43%
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -21.49%
H: 0.56%
C: -12.21%
novartis
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
Published: 2021-11-22 (Crawled : 01:00) - globenewswire.com
HTGC F | $18.25 0.5% -0.27% 550K
|
Finance
|
| O: -0.42%
H: 0.48%
C: -0.78%
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
expansion
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Published: 2021-11-15 (Crawled : 01:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 7.99%
H: 0.0%
C: 0.0%
presentation heart phase 3 trial
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.